In July 2023, Xihua have completed the acquisition of TCM Groups, Inc. (‘TCM’), USA. And then, as one of subsidiary of XIHUA ,TCM will continue to provide clinical trial research professional services to global pharmaceutical companies. Founded in 2003 with offices in New Jersey, TCM Groups, Inc. (TCM) is a contract research organization (CRO) dedicated to providing clinical trial professional services to pharmaceutical companies worldwide. At present, it has provided Clinical Trial Data Management, Statistical Analysis & Programming, Medical Writing, Pharmacovigilance and Government Consultation & Exchange Strategy services for more than 50 pharmaceutical companies around the world. The research projects of TCM mainly focus on oncology, central nervous system, analgesia, cardiovascular diseases, respiratory system and other fields.

TCM is led by Michael Chen, a well-known statistical expert in the United States, the company has a stable international professional team, years of internal standardized management and project experience accumulation, has established a mature and perfect standard operating process and quality management system.

The company focused on small and medium-sized biopharmaceutical companies in the early stage. TCM has based on the core service concept of ‘striving to save costs and create more added value for customers through thorough project design and effective planning in the early stage’ and continuous development, it has provided clinical trial research services for many innovative drug research and development enterprises in Europe and the United States for more than 20 years and established good cooperative relations, accumulated rich FDA application service practices and experience, and established a characteristic FDA communication process on this basis and integrated professional channel resources. A deep understanding of diseases and drugs has been formed.

With over 30 years of experiencing pharmaceutical and clinical CRO statistics & data management; the Head of Statistics and Data Management at Ciba-Geigy Pharmaceuticals, Wyeth Pharmaceuticals previously. Michael Chen has served on Data and Safety Monitoring Board, (DSMB), represented clients at FDA Expert Advisory Committee meetings, participated in international program protocol review, revision, FDA application and other works.

With the successful of this acquisition, XIHUA Clinical, a wholly-owned subsidiary of XIHUA, will further cooperate on the basis of the original in-depth cooperation, continue to fully invest in operations in China and the United States, deeply cultivate clinical trial digital services, accelerate the clinical research process of innovative drugs of pharmaceutical companies, and contribute their own strength to clinical trial research.